PDGF & Receptor Background

Platelet-derived Growth Factor (PDGF) Receptors
Platelet-derived growth factor acts through a cell surface receptor, PDGFR, which is a receptor tyrosine kinase. Two types of PDGFRs have been identified: alpha type (PDGFRA) and beta type (PDGFRB) PDGFRs. The alpha type binds to PDGF-AA, PDGF-BB and PDGF-AB while the beta type PDGFR binds with high affinity to PDGF-BB and PDGF-AB. Upon activation by PDGF, PDGFR dimerise and activate signaling pathway involving gene expression, cell cycle and many other processes.

Platelet-derived Growth Factor (PDGF) Inhibitor
Inhibition of the PDGF signal pathway results in loss of pericytes and a reduction in vessel density in the neovascularized cornea that correlates with reduced expression of PDGF, ang1/2, and VEGF mRNA. PI3-K is known to be involved in the regulation of VEGF, ang1, and PDGF, as the PI3-K inhibitors wortmannin or LY294002 has similar effects. Since PDGF is a known stimulus for PI3-K activation, decrease in VEGF, ang1/2, and PDGF mRNA levels on administration of the PDGF inhibitor is caused by the decreased activation of the PI3-K signaling cascade.

Platelet-derived Growth Factor (PDGF) Signaling Pathway
Platelet-derived growth factor (PDGF) signaling network consists of four ligands, PDGFA-D, and two receptors, PDGFRalpha and PDGFRbeta. All PDGFs function as secreted, disulphide-linked homodimers, but only PDGFA and B can form functional heterodimers. The four PDGF ligands-PDGFA-D are inactive in their monomeric forms. The PDGFs bind to the protein tyrosine kinase receptors PDGFRA and PDGFRB. These two receptor isoforms dimerize upon binding the PDGF dimer, leading to three possible receptor combinations, namely-AA,-BB and-AB. Dimerization can cause the activation of the kinase. Kinase activation is visualized as tyrosinephosphorylation of the receptor molecules, which occurs between the dimerized receptor molecules (transphosphorylation). In conjunction with dimerization and kinase activation, the receptor molecules undergo conformational changes, which allow a basal kinase activity to phosphorylate a critical tyrosineresidue, thereby "unlocking" the kinase, leading to full enzymatic activity directed toward other tyrosine residues in the receptor molecules as well as other substrates for the kinase.

PDGF & Receptor References
  1. Matsui T, et al. (1989) Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 243(4892): 800–4.
  2. Heidaran MA, et al. (1991) Role of alpha beta receptor heterodimer formation in beta platelet-derived growth factor (PDGF) receptor activation by PDGF-AB. J. Biol. Chem. 266(30): 20232–7.
  3. Nobuo Jo, et al. (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. American Journal of Pathology. 168:2036-53.
  4. Ricardo H. et al. (2006) Biology of platelet-derived growth factor and its involvement in disease. Mayo Clinic Proceedings. 81(9): 1241-57.
  5. H N Antoniades, et al. (1981) Human platelet-derived growth factor (PDGF): purification of PDGF-I and PDGF-II and separation of their reduced subunits. PNAS. 78(12):7314-17.
  6. PengF, et al. (2008) Mechanisms of platelet-derived growth factor-mediated neuroprotection--implications in HIV dementia. Eur J Neurosci. 28(7):1255-64.
Browse other Research Tool Reagents at Sino Biological
Virus Research Tools
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"